AU2003200309B2 - Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases - Google Patents
Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases Download PDFInfo
- Publication number
- AU2003200309B2 AU2003200309B2 AU2003200309A AU2003200309A AU2003200309B2 AU 2003200309 B2 AU2003200309 B2 AU 2003200309B2 AU 2003200309 A AU2003200309 A AU 2003200309A AU 2003200309 A AU2003200309 A AU 2003200309A AU 2003200309 B2 AU2003200309 B2 AU 2003200309B2
- Authority
- AU
- Australia
- Prior art keywords
- ischaemia
- cytopathy
- treating
- mammal
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 36
- 201000010099 disease Diseases 0.000 title claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 27
- 230000000302 ischemic effect Effects 0.000 title description 50
- 108010092801 Midkine Proteins 0.000 claims description 230
- 102000016776 Midkine Human genes 0.000 claims description 230
- 208000028867 ischemia Diseases 0.000 claims description 59
- 210000004556 brain Anatomy 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 208000010125 myocardial infarction Diseases 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 26
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 24
- 206010008118 cerebral infarction Diseases 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 20
- 230000000971 hippocampal effect Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 210000002763 pyramidal cell Anatomy 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 description 34
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 33
- 102000005162 pleiotrophin Human genes 0.000 description 33
- 241000700159 Rattus Species 0.000 description 28
- 210000002216 heart Anatomy 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 21
- 206010061216 Infarction Diseases 0.000 description 20
- 230000007574 infarction Effects 0.000 description 20
- 230000001681 protective effect Effects 0.000 description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 19
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 19
- 238000010186 staining Methods 0.000 description 17
- 230000035882 stress Effects 0.000 description 17
- 230000002107 myocardial effect Effects 0.000 description 14
- 230000002861 ventricular Effects 0.000 description 14
- 208000014674 injury Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000004351 coronary vessel Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 241000699684 Meriones unguiculatus Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 235000011089 carbon dioxide Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001052 transient effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004958 brain cell Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 210000004129 prosencephalon Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 239000003900 neurotrophic factor Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 210000001174 endocardium Anatomy 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 238000007914 intraventricular administration Methods 0.000 description 5
- 230000008764 nerve damage Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 102100036197 Prosaposin Human genes 0.000 description 4
- 101710152403 Prosaposin Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010009895 Colitis ischaemic Diseases 0.000 description 3
- 101001046529 Homo sapiens Mevalonate kinase Proteins 0.000 description 3
- 101000990990 Homo sapiens Midkine Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 102000053521 human MDK Human genes 0.000 description 3
- 230000036046 immunoreaction Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- -1 polyvinylpyrroridone Polymers 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008263 repair mechanism Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 2
- 208000019736 Cranial nerve disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000001363 mesenteric artery superior Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-ortho-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101001046530 Mus musculus Mevalonate kinase Proteins 0.000 description 1
- 101000990991 Mus musculus Midkine Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101150073528 PTN gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101001052031 Rattus norvegicus Fibroblast growth factor 2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000013036 cure process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000005110 dorsal hippocampus Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 108700005467 recombinant KCB-1 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
S&FRef: 501775D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicants: Yoshihiro Yoshida 8-10, Sairyo 8-chome Kagoshima-shi Kagoshima 890-0032 Japan Meiji Milk Products Co., Ltd 3-6, Kyobashi 2-chome Chuo-ku Tokyo 104-8381 Japan Actual Inventor(s): Address for Service: Invention Title: Yoshihiro Yoshida, Shinya Ikematsu, Sadatoshi Sakuma, Munehiro Oda Spruson Ferguson St Martins Tower,Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases Technical Field This invention relates to a pharmaceutical composition for preventing or treating ischaemic diseases with midkine (abbreviated as MK hereinafter) as an active ingredient.
Background Art Ischaemia is a condition wherein the blood flow is completely obstructed or considerably reduced in localised parts of the body, resulting in anoxia, reduced supply of substrates and accumulation of metabolites. Although the extent of ischaemia depends on the acuteness of vascular obstruction, its duration, tissue sensitivity to it, and developmental extent of collateral vessels, dysfunction usually occurs in ischaemic organs or tissues, and prolonged ischaemia results in atrophy, denaturation, and necrosis of affected tissues.
Ischaemic cerebrovascular injury development mechanisms are classified into three types, thrombotic, embolic, and amic. The principal pathological condition for all three types is nevertheless cerebral ischaemia, whose severeness and duration define the extent of cerebral tissue injuries. At the site of severe ischaemia, nerve and endothelial cells rapidly suffer from irreversible injuries, forming typical infarction nidi due to necrosis. Although the bloodstream moderately declines and functions of neurocytes are suspended in the ischaemic penumbra, their survival capacity is not lost and the remaining cerebrovascular system can recover its functions when circulation is resumed via collateral vessels.
In ischaemic cardiopathy, which are diseases that affect the coronary artery and cause myocardial ischaemia, the extent of ischaemic myocardial cell injury proceeds from reversible cell damage to irreversible cell damage with increasing time of the coronary artery obstruction.
Drugs for preventing such cytopathy caused by ischaemia or stimulating the regeneration of damaged cells may conceivably provide fundamental therapy of ischaemic cerebral and cardiac disorders.
Based on this concept, drugs efficacious in preventing and treating neurocyte injury following the transient cerebral ischaemia have been reportedly screened by injecting candidate substances for ischaemic brain protective factors into the ventricle or peripheral blood vessel and studying the effect of the substances morphologically and functionally. For example, the intraventricular administration of prosaposin to Mongolian gerbils significantly relieved learning disability after ischaemia, and pathological inspection of the hippocampal CA1 area revealed a remarkable increase of the number of pyramidal cells compared with the control (Sand, A. et al.: Biochem. Biophys. Res. Commun. 204: 994-1000, 1994). Like prosaposin, it has been proven that the intraventricular injection of ciliary neurotropic factor (CNTF) and interleukin 6 (IL-6) also significantly increased, in a dose-dependent manner, the number of pyramidal cells and synapses in the CA1 area (Wen, T-C et al.: Neurosci. Lett.
191: 55-58, 1995) (Matsuda, S. et al.: Neurosci. Lett. 204: 109-112, 1996). The intraventricular injection of basic fibroblast growth factor (bFGF) has also been reported to significantly protect against ischaemic hippocampus, though not in the same way as prosaposin, CNTF and IL-6 (Wen, T-C et al.: [R:\LIBVV]03001 .doc:G DR SNeuroscience, 65: 513-521, 1995). However, action mechanisms of these protective factors for ischaemic brain disorders have not been clarified in detail.
O Disclosure of the Invention The present invention provides a novel pharmaceutical composition for treating or preventing various diseases caused by cell death due to ischaemia or stress, which c comprises a midkine (MK) family protein as an active ingredient.
According to a first embodiment of the present invention there is provided a method Cc for treating or preventing cytopathy caused by ischaemia or stress in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a to pharmaceutical composition comprising a midkine (MK) family protein as an active ingredient.
According to a second embodiment of the present invention there is provided a method for treating or preventing diseases caused by cytopathy due to ischaemia in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition comprising a midkine (MK) family protein as an active ingredient.
According to a third embodiment of the present invention there is provided a method for treating or preventing cerebral infarction caused by cytopathy due to stress in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition comprising a midkine (MK) family protein as an active ingredient.
According to a fourth embodiment of the present invention there is provided use of a midkine (MK) family protein for the manufacture of a medicament for treating or preventing cytopathy caused by ischaemia or stress.
According to a fifth embodiment of the present invention there is provided use of a midkine (MK) family protein in the manufacture of a medicament for treating or preventing diseases caused by cytopathy due to ischaemia.
According to a sixth embodiment of the present invention there is provided use of a midkine (MK) family protein in the manufacture of a medicament for treating or preventing cerebral infarction caused by cytopathy due to stress.
According to a seventh embodiment of the present invention there is provided a midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing cytopathy caused by ischaemia or stress in a mammal.
I\O According to a eighth embodiment of the present invention there is provided a midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing cytopathy caused by O ischaemia or stress in a mammal, wherein said cytopathy occurs in brain parenchyma.
According to a ninth embodiment of the present invention there is provided a c midkine (MK) family protein or a pharmaceutical composition comprising an MK protein O as an active ingredient when used for treating or preventing cytopathy caused by ischaemia or stress in a mammal, wherein said cytopathy occurs in brain parenchyma which is pyramidal cells in the hippocampal CA1 area.
According to a tenth embodiment of the present invention there is provided a midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases caused by cytopathy due to ischaemia in a mammal.
According to an eleventh embodiment of the present invention there is provided a midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases caused by cytopathy due to ischaemia or stress in a mammal, wherein said disease is cerebral infarction.
According to a twelfth embodiment of the present invention there is provided a midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases caused by cytopathy due to ischaemia in a mammal, wherein said disease is myocardial infarction.
Midkine (MK) is a heparin-binding secretory protein abundant in basic amino acids and cysteine. It was discovered as the product of a gene that was transiently expressed in the differentiation process of embryonic tumour cells induced by retinoic acid (Kadomatsu, K. et al.: Biochem. Biophys. Res. Commun. 151: 1312-1318, 1988; Tomomura, M. et al.: J. Biol. Chem. 265: 10765-10770, 1990; Tomomura, M. et al.: Biochem. Biophys. Res. Commun. 171: 603, 1990). MK shares 45% homology with pleiotrophin (PTN) discovered later (Merenimies, J. Rauvala, J. Biol. Chem. 265: 16721-16724, 1990), and MK and PTN thus form the MK family (Muramatsu, Dev.
Growth Differ., 36: 1-8, 1994).
r"~l rn~r~llOOC~ JTI (Z Many data on the function of MK have been accumulated, and its more novel Simportant functions are now very likely to be discovered. Principal functions of MK include the following five functions: 1) neurotrophic factor activity (MK stimulates the survival and neurite outgrowth of neurocytes (Muramatsu, H. et al.: Dev. Biol., 159: 392, 1993; Michikawa, M. et al.: J. Neurosci. Res., 35: 530, 1993; Kikuchi, S. et. al., 160, 1993)); 2) wound healing (MK alleviates and prevents retinal denaturation due to the 0prolonged irradiation by white light (Unoki, K. et al.: Ophthalmol. Vis. Sci., 35: 4063, ¢C 1994) and expression of MK is induced near infarct nidi in the early stage of experimental O cerebral and myocardial infarctions in rats (Yoshida, Y. et al.: Dev. Brain Res., 85; 25-30, 1995; Obama, H. et al.: Anticancer Research, 18: 145-152, 1998)); 3) ontogenesis (MK is transiently expressed with a peak in the embryonal mid stage, and accumulates mostly in the kidney in the late stage); 4) activation of fibrinolytic system (MK increases three- to five-fold the plasminogen activator activity of vascular endothelial cells derived from bovine aorta at a concentration of 10ng/mL (Kojima, S. et al.: J. Biol. Chem., 270: 9590, is 1995)); and 5) cancer (MK is expressed in a high frequency in Wilms' tumour, breast cancer, lung cancer, neuroblastoma, oesophagus cancer, stomach cancer, colon cancer, and hepatoma (Tsutsui, J. et al.: Cancer Res., 53: 1291, 1933; Garver, R. et al.: r.T 4j-.--rTr Cancer, 74: 1584, 1994; Garver, R. et al: Am. J. Respir. Cell Mol. Biol., 9: 463, 1993; Nakagawa, A. et al.: Cancer Res., 55: 1792, 1995; Aridome, K. et Jpn. Cancer Res., 86: 655, 1995).
As described above, the expression of MK is induced near infarct nidi in the early stage after the experimental cerebral infarction in rats, and it has been demonstrated that it was expressed exclusively in astrocytes (Yoshida, et Dev. Brain Res., 85: 25-30, 1995). PTN, which forms the family together with MK, is also strongly expressed in the hippocampus, mainly in the CA1 area, and mostly in astrocytes, of rat on the fourth day after development of the transient ischaemia in the rat forebrain (Takeda, A. et Neuroscience, 68: 57-64, 1995). Conventionally, the activation of astrocytes that accompanies ischaemia has been understood to protect cells. MK and PTN may play a role in the repair process of central nervous system after development of ischaemia.
The present inventors assumed that MK might be transiently expressed in human patients with cerebral infarction after onset of the disorder and determined MK concentrations in sera from 150 healthy individuals and 36 cerebral infarction patients. The average serum concentration of MK in healthy individuals was found to be 0.3ng/mL compared with 0.9ng/mL in patients. Furthermore, MK is concentrations tended to be higher in the serum samples collected from the patients right after development of the disorder and from patients having greater infarction areas. These phenomena are assumed to be due to the circulation of MK transiently expressed near the ischaemic region.
Recently, increased expression of various neurotrophic factors in nerve injuries caused by trauma, ischaemia, etc. has been reported (Frautschy, S. A. et Brain Res., 553: 291, 1991; Haynes, L. Neurobiol., 2: 263, 1988). These neurotrophic factors are probably involved in repair mechanisms of nerve injuries and act on neurocytes either directly or indirectly via gliacytes to play important roles in their survival and repair.
Based on these reports, the present inventors examined whether MK is involved in mechanisms of repairing nerve injuries like other neurotrophic factors using an experimental model of cerebral ischaemia. MK was intraventricularly injected into Mongolian gerbils, one such model, before and after the operation to develop ischaemia in order to morphologically examine suppressive effects of MK on deciduation of hippocampal CA1 neurons. Since the anastomosis of internal carotid artery and vertebral artery systems in Mongolian gerbils, retracts after the age of eight weeks, an excellent model of incomplete forebrain ischaemia can be readily prepared by obstructing the bilateral common carotid arteries with clips for three to five minutes so that a certain denaturation of neurocytes (delayed neurocyte death) is caused in a specific site (hippocampal CA1 area) in 48 to 72 hours by reperfusion following ischaemia. Therefore, a transient forebrain ischaemia model of Mongolian gerbils is useful for assessing protective factors for ischaemic brain (Kirino, T. et Brain Res. 237: 57-69, 1982; Mitani, A. et Neurosci. Lett. 131: 171-174, 1991).
MK was intraventricularly injected into Mongolian gerbils prior to the ischaemic operation to examine its protective effects on ischaemic brain. A 2mm-deep hole was made 2mm from the bregma of a Mongolian gerbil, and physiological saline containing MK (0.063, 0.125, 0.25, 0.5, 1.0 and PTN 1.0 and 2.0pg), or, for comparison, bFGF (1.0 and 2.0pg), which is known to have protective effects on the ischaemic brain, was intraventriculary injected into the animals. After four minutes, the bilateral common carotid arteries were ligated to obstruct the circulation for five minutes [R:\LIBVV]03001 .doc;GDR so that a transient ischaemic forebrain model was prepared. Ninety-six hours or seven days after the circulation was resumed, the brain was excised and fixed under perfusion with 4% oaraformaldehyde.
From the paraffin block thus prepared, 5-0m thick sections were prepared and stained with haematoxylin-eosin to count the number of viable neurocytes per 1mm of the left hippocampal CAl s area. As shown in Tables 1 and 2, deciduation of hippocampal CA1 neurocytes was significantly suppressed in the MK (0.5pg or more) administered group and in the PTN (2.0pg or more) administered group as compared with the control group (injected with physiological saline).
bFGF significantly suppressed deciduation of hippocampal CA1 neurocytes at a concentration of 2.0pg or more as compared with the control group. These results indicate that the previous administration of MK or PTN into the ventricle can suppress (prevent) brain cell injury caused by ischaemia and the subsequent perfusion.
In addition, MK was intraventricularly administered to Mongolian gerbils after the ischaemic operation to examine its protective effects on ischaemic brain. After the transient forebrain ischaemia was constructed in the same manner as described above, blood circulation was resumed, and 48 hours later MK was intraventricularly injected in the same manner as above. On day seven after the injection, 5pm thick sections were prepared similarly as described above and stained with haematoxylin-eosin to count the number of viable neurocytes per millimetre of the area of the left hippocampal CA1 neurocytes. About 160 viable neurocytes per mm of hippocampus were observed (Example This number of viable cells is about the same as that when 0.5pg of MK was administered just prior to the ischaemic operation.
High-level mentation such as memory or learning is definitely the basis of mental activity in humans. Therefore, the development of drugs capable of reducing hindrances to memory and learning has become one of the most interesting tasks in neuroscience. Many experimental models of memory or learning hindrance are known, and test methods thereof are extremely various. One such test, the passive avoidance learning test, is frequently used with mice.
In arriving at this invention, the present inventors clarified that intraventricular administration of MK or PTN within a certain period before or after a transient forebrain ischaemia operation significantly suppresses deciduation of hippocampal CA1 neurocytes as compared with control.
Furthermore, the number of hippocampal neurocytes reportedly correlates well with the improvement of response lag time in the step-down type passive avoidance learning test (Araki, H. et al: Physiol.
Behav. 38: 89-94, 1986; Sano, A. et al.: Biochem. Biophys. Res. Commun. 204: 994-1000; Wen, T.-C.
et al.: Neuroscience, 65: 513-521; Wen, et al.: Neurosci. Lett. 191: 55-58). Therefore, the response lag time can be improved by intraventricular injection of MK or PTN before or after ischaemic loading.
The fact that hippocampal CA1 neurocytes are most easily injured by cerebral ischaemia and the subsequent perfusion, the experimental results that the deciduation of hippocampal CA1 neurocytes in animal groups injected with MK or PTN before or after ischaemia was significantly suppressed as compared with control groups, and the report suggesting that MK or PTN improves the response lag time in the step-down type passive avoidance learning test all indicate that MK or PTN can be expected to be useful both for preventing and treating neurocyte injury caused by cerebral [R:\LIBVV)03001 .doc:GDR ischaemia and subsequent perfusion and for improving mental disorders, which is the ultimate purpose of these remedies.
In addition, Example 3 below reveals that, in the case of nerve cell injury caused by both ischaemic stress and other stresses such as traumatic stress, MK, in response to the early stage of such injury, is expressed near the injured sites.
Therefore, MK or PTN can be used to prevent or treat various cranial nerve disorders by directly preventing the dysfunction, denaturation and cell death of neurocytes in overall or specific regions from fundamental causes such as ischaemia, trauma and aging or no accountable causes, and by stimulating the regeneration of injured neurocytes. In addition, using MK combined with other neurotrophic factors such as bFGF having different action mechanisms may produce synergistic or additive protective effects to prevent neurocyte death caused by ischaemia or stress. Specific disorders to be treated may include cerebral infarction, transient cerebral ischaemia, encephalopathy due to the cerebrovascular spasm such as sequela of subarachnoid haemorrhage, senile dementia, and encephalopathy at the time of anabiosis following cardiac arrest.
The present inventors also constructed an experimental cardiac infarction model by ligating the left descending coronary artery of rat to detect the MK expression in cardiac cells by immunohistochemical staining (Obama, et at: Anticancer Research, 18: 145-152, 1998). The results indicated that the expression of MK was not observed in most of cardiac cells in a normal heart, but was observed in cardiac cells at several places facing the ventricle (Figs. 4 and In contrast, strong expression of MK was observed in the cardiac infarction model heart on the wall of the right ventricle the septum, and the endocardium of the wall of the left ventricle facing the right ventricle (LV) (Fig. Other areas on the left ventricular wall corresponding to the cell death region were not stained. Specificity of this MK staining was confirmed because the MK staining disappeared after MK was absorbed by an anti-MK antibody (Fig. Thus, the present inventors immunohistochemically demonstrated the distinct expression of MK in cardiac infarction. Surprisingly, the remarkably intensified MK staining was observed not only in the region adjacent to the infarction site of the left ventricle but also in the entire RV and most areas of the septum (Fig. 6).
Stained and unstained regions are divided by a distinct line that corresponds to the border between coronary artery regions. Interestingly, the expression pattern of MK in a cardiac infarction model differs from that of bFGF in the same model (not shown in the figure).
More detailed examination of MK expression in an infarction model revealed the appearance of MK staining in the RV (Fig. 8) and septum (Fig. 9) (indicated by an arrow and an arrowhead). The septum was extensively magnified, and intense staining was observed at capillaries or the penumbra of myocardial cells facing capillary endothelium (Fig. 10). The interior of myocardial cells is also intensely stained (indicated by asterisk). The stained region was clearly separated from the unstained region by the border between the septum and LV (Fig. 10). As described above, only a slight and uneven MK staining is observed in LV, except for endomyocardial cells (Fig. 12).
Comparison of mRNA expression in the RV and septum of the infarction model and normal rats by Northern blot analysis revealed that the increased mRNA level is detectable in infarction model rats. In addition to the 1.0kb MK mRNA, a 1.8 kb band reacting with MK cDNA was detected. This [R:\LIBVV]03001.doc:GDR 1,8kb band might be an isoform of MK mRNA. These results indicate that the increased MK immunoreactivity in the heart shortly after infarction is caused by stable elevation of transcription activity of mRNA.
MK expression is remarkably enhanced in myocardial infarction caused by ligating the left anterior coronary artery (LAD) of a rat. This enhancement is attributed to increased MK mRNA, and is generated in the early stage, within six hours after infarction. In spite of MK expression in a broad area of an infarcted heart, its expression is not detected in regions destined to cell death, indicating that MK is involved in the repair of damaged cardiac tissues.
Considering the fact that, as described above, MK is expressed in the oedematous area near necrotic sites shortly after cerebral infarction, the expression of MK indicates its possible participation in the repair or cure process under various pathological conditions. In fact, it has been demonstrated that prior administration of MK prevents the retinal denaturation caused by continuous exposure to light irradiation (Unoki, et al, Invest. Ophthalmol. Vis. Sci., 35: 4063-4068, 1994).
bFGF expression is associated with myocardial infarction and has cardioprotective action (Speir, et al.: Circ. Res., 71: 215-259, 1992). However, the present inventors could clearly demonstrate that MK was more highly expressed than bFGF under experimental conditions we selected. MK and bFGF jointly increase the plasminogen activator activity in aortic endothelial cells (Kojima, et al.: J. Biol. Chem., 270: 9590-9596, 1995). They also enhance proliferation of tooth mesenchymal cells (Mitssiadis, T. et al,: J. Cell Biol., 129: 267-281, 1995). Therefore, they may also act in concert in repairing injured cardiac tissues.
In addition, the present inventors have found that MK is also expressed slightly in myocardial cells, and highly expressed in endocardium in normal hearts. This localised expression of MK resembles that of bFGF (Speir, et Circ. Res., 71: 215-259, 1992), but their increasing patterns of expression after infarction differ from each other. In normal myocardial cells, bFGF is thought to be involved in promoting DNA synthesis, stimulating survival, retarding aging, and regulating migration and production of extracellular matrix (Speir, et al.: Circ. Res., 71: 215-259, 1992). MK might also be playing similar roles in the heart. MK expression after cardiac infraction is enhanced in areas not only proximal but also distal to the infarcted region. This enhanced expression of MK is detected in not only ventricles but also walls of the atria.
From these facts, it is obvious that MK plays important roles in both the generation and repair of the heart, indicating the possibility that abnormality in the expression of MK or signal transduction system may cause various disorders including cardiac disease. Therefore, MK is thought to be useful as a medicament for preventing or treating ischaemic cardiac diseases such as myocardial infarction leading to myocardial necrosis due to the obstruction of the coronary artery or acute reduction of blood circulation. Furthermore, MK or PTN can be used as a medicament for preventing or treating a group of other disorders caused by cytopathy due to ischaemia and stress such as ischaemic colitis or mesenteric artery occlusion caused by circulation disturbance in the digestive tracts.
MK or PTN of this invention used for treating or preventing disorders due to cytopathy caused by ischaemia is preferably a human recombinant MK or PTN, or partial peptide fragments thereof having their biological activities. Native MK is not glycosylated; unglycosylated MK is thus preferable [R:'L[BVVJ~3001 .doc:GDR in the present invention. Such MK includes human MK consisting of 121 amino acid residues, but its amino acid sequence is not limited thereto (Muramatsu, Develop. Growth Differ. 36: 1-8, 1994).
In mouse MK, a signal peptide is cleaved from a precursor protein consisting of 139 amino acid residues to yield the mature MK (consisting of 118 amino acid residues with a molecular weight of 13kDa). Thirty of these amino acid residues are basic amino acids, and 10 are cysteine residues.
Five disulfide linkages formed by the cysteine residues construct two domains at the N- and C-termini.
These two domains differ in biochemical and biological properties and may possibly play different roles in in vivo functional expression. The heparin-binding capability is higher on theC-terminus side than the N-terminus side (Muramatsu, et al.: Biochem. Biophys. Res. Commun., 203: 1131, 1994).
Capabilities for neurite outgrowth and fibrinolysis stimulation are mainly bound in the C-terminus (Muramatsu, et at: Biochem. Biophys. Res. Commun., 203: 1131, 1994; Kojima, et al.: Biochem. Biophys. Res. Commun., 206: 468, 1995). Therefore, partial polypeptide fragments having biological activities intrinsic to MK are also included in this invention.
Specific amino acid(s) in the amino acid sequence of human MK can easily be deleted, inserted, or substituted using recombinant DNA techniques to enhance the activities of the drugs of this invention or improve their safety. For example, amino acid at a specific site can be chemically substituted with its equivalent amino acid. Specifically, a hydrophobic amino acid (such as Ala) can be substituted with both another amino acid (such as Gly) with comparable hydrophobicity and an amino acid with higher hydrophobicity (such as Val, Leu or lie). Similarly, one negatively charged amino acid residue can be substituted with another amino acid (eg. replacing Asp with Glu), or one positively charged amino acid residue with another amino acid (eg. replacing Lys with Arg). In addition, since the C-terminal half of MK, for example, positions 60-121 (C-half 60-121), or positions 62-104 from the C-terminus (C-half 62-104) (Muramatsu, H. et al.: Biochem. Biophys. Res. Commun.
203: 1131-1139, 1994) carries the neurite outgrowth capability and contains the heparin-binding site, they can be useful for drugs of this invention. Also, a hydrophobic amino acid is desirably altered to a charged amino acid as long as such alteration produces no undesirable effect on the biological activity of MK. Those skilled in the art can perform the above modifications so that MK has preferable biological activities. MK and PTN cannot exhibit their efficacy because of the attack from proteinases and interference by unnecessary receptors, like proteinaceous drugs often cannot. Therefore, the stability of MK and PTN in vivo can be elevated by conjugating them with polyethyleneglycol (PEG), polyvinylpyrroridone, dextran, etc. For example, IL-6 hybridised with PEG successfully prolonged the residence of IL-6 in the bloodstream. This invention also includes such chemically modified MK and
PTN.
The term "midkine" or "MK" used herein includes all of such modified and altered MKs as long as they retain the original biological activities of MK. The term "MK family" used herein includes all of these modified and altered proteins (MK and PTN) belonging to this family as long as they have biological activities intrinsic to them.
An MK family protein of the present invention can be directly administered to prevent or treat cerebral infarction, myocardial infarction, ischaemic colitis, superior mesenteric artery occlusion, etc.
Alternatively, it can be formulated into a pharmaceutical composition comprising the active ingredient [R:\LIBVVI03001.doc:GDR by known pharmaceutical preparative methods. For example, it can be formulated into pharmaceutical preparations suitable for effectively administering to human subjects. This includes injection, preparations for nasal inhalation, percutaneous absorption, oral administration, etc., preferably injection. The preparations are administered together with pharmaceutically acceptable carriers or media such as sterilised water, physiological saline, plant oil (eg. sesame oil, olive oil, etc.), colorant, emulsifier (eg. cholesterol), dispersant (eg. gum arabic), surfactant (eg. polyoxyethylene hydrogenated castor oil surfactant), solubiliser (eg. sodium phosphate), stabiliser (eg. sugar, sugar alcohol and albumin), preservative (paraben), etc. Injectable preparations can be provided in the form of lyophilisates, aqueous solution, and products sealed into an osmotic pressure pump.
Pharmaceutical preparations of this invention contain MK or PTN, which directly act on the cerebral parenchyma and myocardial cells to exhibit its efficacy. Thus, unlike nosotrophic drugs such as conventionally used cerebral metabolic stimulators and cerebral circulation improving agents, the preparations of this invention can be used to treat various cranial nerve disorders by directly preventing the dysfunction, denaturation and necrosis of neurocytes in overall or specific regions due to fundamental causes such as ischaemia, trauma and aging or no accountable causes, and by stimulating the regeneration of injured neurocytes.
The above disorders can be treated by gene therapy by enhancing the expression of MK or PTN protein in ischaemically diseased sites using the promoter region of the MK or PTN gene.
The pharmaceutical composition of this invention can be injected, for example, at a daily dose of about 0.001 to 100pg/kg of MK or PTN protein divided into one to six dosages, intraarterially, intravenously, intramascularly, subcutaneously, intraventricularly, or intraspinally. The composition can also be administered directly into the ventricle and meninx via a catheter inserted therein.
Alternatively, it can be incorporated into an osmotic pressure pump and continuously administered via the pump implanted in the body.
It has been reported that the permeability of the blood-brain barrier isltransiently elevated by infusing a hypertonic solution of mannitol, urea, etc. via the carotid artery (Proc. Natl. Acad. Sci. USA 76: 481-485, 1979), and that some substances (ie. alkylglycerol) promote the intracerebral transfer of other drugs. The pharmaceutical composition of this invention can also be administered using these techniques. Furthermore, the possibility of intracerebral uptake of cationised albumin by some mechanisms has been reported Clin. Invest. 70: 289-295, 1982). MK or PTN proteins may be administered after they are chemically modified by such a method.
Brief Description of the Drawings Figure 1 presents photomicrographs (x10) of brain cells two days after being treated with dry ice. A shows the cells in the area infarcted by the dry ice treatment and its vicinity stained with haematoxylin-eosin (H-E staining). B shows an image of an H-E stained, highly injured infarcted area.
C shows an image of a similar area to that of B stained with an anti-MK antibody.
Figure 2 presents photomicrographs of brain cells two days after being treated with dry ice. D is an enlarged (x50) view of cells near the infarcted area that react with an anti-MK antibody. E shows a similar area to that of D that is apoptosis-stained by the TUNEL method (using a TaKaRa In situ [R:LIBVV03001 .doc:GDR Apoptosis Detection Kit). TUNEL reaction-positive cells resulting in apoptosis following the fragmentation of nucleus are observed.
Figure 3 presents photographs of brain cells from a head trauma model rat. A, C, and E are stained with H-E. B, D, and F are images corresponding to A, C and E stained with an anti-MK antibody. Magnifications are 25-fold for A and B, and 100-fold for C, D, E and F.
Figure 4 is a photomicrograph showing the distribution of MK in a normal heart.
Figure 5 is a photomicrograph showing the distribution of MK in a normal heart.
Figure 6 is a photomicrograph showing the distribution of MK in a rat heart after the obstruction of the left anterior descending coronary artery.
Figure 7 is a photomicrograph showing the distribution of MK in a control of the rat heart after the obstruction of the left anterior descending coronary artery.
Figure 8 is a photomicrograph showing the distribution of MK on the right ventricular wall of a rat heart six hours after the formation of myocardial infarction.
Figure 9 is a photomicrograph showing the distribution of MK in the septum of a rat heart six hours after the formation of myocardial infarction.
Figure 10 is a photomicrograph showing the distribution of MK in the border region of the septum, and the ventricular wall and the left ventricular wall with the infarcted site of a rat heart six hours after the formation of myocardial infarction.
Figure 11 is a photomicrograph showing the distribution of MK in the septum of a rat heart six hours after the formation of myocardial infarction.
Figure 12 is a photomicrograph showing the distribution of MK in the left ventricular wall of a rat heart six hours after the formation of myocardial infarction.
Figure 13 is a photomicrograph showing the distribution of MK in the endocardium of the left ventricle of a rat heart six hours after the formation of myocardial infarction.
Figure 14 is a graph showing the result of periodic measurement of MK concentration in serum from a myocardial infarction patient.
Figure 15 is a graph showing the result of periodic measurement of MK concentration in serum from a cerebral infarction patient, Best Mode for Implementing the Invention Example 1 Assessment of ischaemic brain protective substances in a transient forebrain ischaemia model 1.1 Administration of ischaemic brain protective substances prior to ischaemic operation 1,1.1 Ischaemic brain protection by MK Recombinant human MK was prepared according to the method described in Example 1 of Unexamined Published Japanese Patent Application (JP-A) No. Hei 9-95454, and used in Example 1.1.2 and Example 1.2. Six to 16 male Mongolian gerbils (six to eight weeks old, weighing 60 to for each group were placed in "HONEY MATIC M-3" (KIMURA MEDICAL INSTRUMENT LTD.), an anaesthetic feeding system for fluothane (halothane in Japanese Pharmacopoeia), and anaesthetised by appropriately filling the container with an inhalation anaesthetic, fluothane. A Mongolian gerbil was fixed onto an operation table equipped with a holder for an insufflator (NARISHIGE SCIENTIFIC INSTRUMENT LAB.: TYPE SR-5N, No. 97024). After the head was subjected to midline incision, a [R:'\LIBVV]03001 -doc:GDR hole for inserting a syringe of an appropriate size was made by a dental drill at 2mm from the site of bregma toward the left eyeball side. Through this hole, 2pL of MK 0.5mg/mL, lmg/mL or 2mg/mL solution (0.5pg, 1.0pg, 2.0pg (in physiological saline) was injected into the ventricle with a microsyringe (HAMILTON MICROLITER #701). A saline (Japanese Pharmacopoeia, physiological s saline, Otsuka physiological saline injection, Otsuka Pharmaceutical) administered group and the sham operation group (Sham-op) were prepared as control groups. After these solutions were injected into the ventricle, the animals were left for 4 min and the operation site was sutured. The chest was subjected to midline incision to expose both right and left common carotid arteries. Both arteries were ligated with "No. 23 artery Kremmer straight" to stop blood flow for 5 min, after which the blood was permitted to circulate again. During ischaemia loading, brain temperature and body temperature were maintained constant (37 0.2 0 Individual was distinguished and housed in the nursery cage after recovering from anaesthesia. The animals were fed and allowed to take water and food freely. After 96 hours, the animals were fixed by perfusing with saline containing 0.2% heparin (Novo Heparin Injection 100; Japan Hoechet Marion Russell, LTD.) and 4% paraformaldehyde solution. The brain was excised from the beheaded head using scissors, and immersed in 4% paraformaldehyde fixative for one day. Tissues containing dorsal hippocampus were dehydrated and penetrated, then embedded in paraffin.
The inventors prepared 5pm sections, equivalent to 0.5 to 1.0mm from the tip of the hippocampus or 1.4 to 1.9mm rear from sagittal suture prepared from this paraffin block and stained with haematoxylin-eosin (H-E staining). Using this tissue preparation, the length of hippocampal CA1 was measured five times using a curvimeter one-side type, and the average value thereof was calculated. Pyramidal cells (neurocytes) of the left hippocampus in the hippocampal region were counted under 200-fold magnification, and the result was divided by the above-described average value to calculate the number of viable neurocytes per mm of the hippocampal CA1. The results are shown in Table 1.
Table 1 Dose (pg) Number of Number of CA1 neurocyte animals (cells/mm)±S.E.
Sham-op group -4 237.5±34.59* Physiological saline administered group 6 9.6±10.31 MK administered group 0.5 4 232.4±17.75* MK administered group 1.0 5 221.6±11.04* MK administered group 2.0 4 236.2±40.02* *p<0.05 (multiple Dunnett comparison) As clearly shown in Table 1, MK administered in a single dose of 0.5pg or more remarkably prevented the delayed neurocyte death in the hippocampal CA1 region.
1.1.2 Comparison of MK's ischaemic brain protective effect with that of other ischaemic brain protective factors Each ischaemic brain protective factor was intraventricularly administered at a dose of 2pL each. The bilateral common carotid arteries were each ligated using Sugita brain aneurism clips (standard type; MIZUHO) at two sites. The brain was fixed by perfusion one week later. With exception of these three modifications, the experiment was performed in the same manner as in 1.1.1.
[R :\LBVVI3001 .doc:GDR Recombinant human pleiotrophin (PTN) and recombinant human basic fibroblast growth factor (bFGF) were purchased from R D Systems (Funakoshi). Their doses were 2pg, 1pg, and 0.5pg for PTN, and 2pg and 1pg for bFGF. The results are shown in Table 2.
Table 2 Dose (pg) Number of Number of CA1 neurocytes animals (cells/mm±S.E.) Sham-op group -4 237.5±34.59 Physiological saline administered group -16 15.7±24.43 MK administered group 0.063 6 12.6±6.41 0.125 10 83.4+111.9 0.25 15 28.3+57.70 6 199.5±99.03* 8 208.5±80.18** 10 219.4±73.87*** PTN administered group 0.5 2 26.1±4.03 2 43.8±0.78 2 179.4±33.02* bFGF administered group 1.0 3 28.8±28.89 7 98.3±74.66* *p<0.05, 0.001 (multiple Dunnett comparison) Also in this example, the dose at which MK exerts statistically significant protective effect on ischaemic brain is assumed to be 0.5pg or more, which is about the same as that obtained in 1.1.1.
Although more neurocytes survived at a dose of 0.125pg than in the physiological saline administered group, the difference was not statistically significant. The dose of PTN required to exert statistically significant protective effect on ischaemic brain was approximately 2pg, which is about four times higher than that of MK. bFGF, which is reportedly effective in protecting an ischaemic brain (Nakata, N. et al.: Brain Res., 605: 354-356, 1993), exerted statistically significant protective effect on an ischaemic brain at a dose of 2pg, but the number of viable neurocytes at that dose was less than about half of that obtained at the same dose of MK. From these results, it is evident that MK, as a suppressor for cranial nerve cell death caused by ischaemia, shows ischaemic brain protective effect in a transient ischaemic forebrain model of Mongolian gerbil comparable to that obtained using known ischaemic brain protective factors such as prosaposin, ciliary neurotrophic factor (CNTF) or interleukin 6 (IL-6).
1.2 Administration of ischaemic brain protective factors after predetermined time of reperfusion following ischaemic operation Except for administering MK 48 hours after reperfusion following an ischaemic operation, the experiment was carried out exactly in the same manner as in 1.1.2. When 2pg MK was administered, the number of viable hippocampal CA1 neurocytes after 48 hours was 160 cells/mm hippocampus.
This was approximately equal to the number obtained at a dose of 0.5pg in 1.1.2. This result revealed that MK administration within a certain time after reperfusion following transient brain ischaemia can effectively protect an ischaemic brain.
As demonstrated above, the MK family proteins may possibly exert ischaemic brain protective effects based on a different action mechanism from that of the known proteinaceous ischaemic brain protective factors. The expression and increase of various neurotrophic factors upon nerve injuries caused by trauma, ischaemia, etc. have recently been reported. It is assumed that these neurotrophic [R:\LIBVV]0300 .doc:GDR factors are involved in repair mechanisms of nerve injury, and act on neurocytes directly or indirectly via gliacytes to play important roles in their survival and restoration. Thus, synergistic or additional effects can be expected by using MK in combination with other neurotrophic factors.
Example 2 Expression of MK in dry ice brain injury (cold injury) model Ten male Sprague-Dawley rats (SD rats) (body weight, 160g) were used. They were anaesthetised by intraperitoneal injection of 4% chloral hydrate (lOmLUkg). Scalp was incised with scissors, and dry ice cut into a 7mm x 10mm piece (about 2mm thick) was pressed from over the skull for 10 seconds. The scalp was then sutured, and animals were fed again and allowed to take water and food freely. On Days 1, 2, 4, 7, and 14 after the dry ice treatment, two rats were anaesthetised by intraperitoneal injection of 4% chloral hydrate (10mUkg), and fixed by perfusing physiological saline (Japanese Pharmacopoeia, physiological saline, Otsuka physiological saline injection, Otsuka Pharmaceutical) containing 0.2% heparin (Novo heparin injection 100; Japan Hoechst Marion Roussel) and 4% paraformaldehyde fixative. After being thoroughly fixed, animals were decapitated.
Their brains were taken out using scissors and soaked in the 4% paraformaldehyde fixative. After fixation for 24 hours, the sufficiently solidified brain was divided into four pieces from the front end using a double-edged razor (FEATHER). Tissue slices in which the infarcted area could be observed were dehydrated, penetrated, and embedded in paraffin using an automatic embedding machine.
From this paraffin block were prepared 5pm-thick sections. These paraffin slices were subjected to 1) haematoxylin-eosin staining (H-E staining), 2) anti-MK antibody (rabbit anti-mouse MK polyclonal antibody) staining, and 3) apoptosis detection.
Figure 1 is a photomicrograph (x 10) of brain cells two days after the dry ice treatment stained with H-E or anti-MK antibody. A represents infarction nidi produced by dry ice and cells near it, B represents extensively injured infarction nidi, and C represents an area similar to that of B stained with the anti-MK antibody. In C (anti-MK antibody staining), high-level expression of MK is observed near the infarcted area.
Figure 2 is a photomicrograph (x 10) of brain cells two days after the dry ice treatment stained with the anti-MK antibody or stained for detection of apoptosis. D represents an enlarged (x 50) view of cells near the infarcted area that reacted with the anti-MK antibody. E represents a photomicrograph of cells near the infarcted area similar to D that were examined by the TUNEL method (using a TaKaRa In situ Apoptosis Detection Kit) to determine whether they caused apoptosis.
Cells with nuclear fragmentation and positive to TUNEL reaction can be detected. As shown in Fig. 2, the more faintly the infarction nidi were stained, the higher damage the cells received.
Example 3 Expression of MK in rat brain injury model In Example 2, MK expression was examined in a model of cerebral infarction caused by ischaemia. In this example, a model of infarction caused by mechanical stress was prepared to examine MK expression therein. Ten male SD rats (body weight, 320g) were used. They were anaesthetised by intraperitoneal injection of 4% chloral hydrate (1OmL/kg). The cerebral cortex was ablated to prepare a brain injury model. Scalp was incised with scissors, and a 4mm diameter, 3mm [R:LIBVV]03001 .doc:GDR thick portion of the cerebral cortex was ablated at 3 mm toward the left eye along the coronal suture and a further 3mm toward the occiput along the sagittal suture. A Dispopunch (disposable skin trepan) (Stiefel Laboratories) was used for ablation. After the complete ablation was confirmed, the scalp was sutured, and the animals were fed again with free access to water and food. On each of Days 1, 2, 4, 7, and 14 after the preparation of the brain injury model, 5 im-thick slices were prepared from two rats in a similar manner as in Example 2. Their paraffin sections were prepared and stained with H.E and anti-mouse MK antibody. The results obtained on Day 1 after the preparation of the brain injury model are shown in Fig. 3; panels A, C and E present H-E staining, and panels B, D and F present anti-MK antibody staining. The panels confirm that MK reacts very quickly to mechanical injuries. Images A, C, and E of H-E stained tissues indicate that brain cells suffered from great damage by mechanical injuries. Images B, D, and F of the tissues stained with the anti-MK antibody show many cells positive to the antibody staining mainly near the haemorrhoidal area and in the area where brain cells were highly damaged, which corresponds to the area stained in A, C, and E. These results clearly demonstrate that, even in the case of neurocyte suffering from injury caused by both ischaemic stress and mechanical stress, MK responds to the injury at the early stage and is expressed near the injured area.
Example 4 Expression of MK in myocardial infarction model 4.1 Preparation of myocardial infarction model An experimental myocardial infarction was prepared on the left ventricular wall of Wistar rats (7week-old, male) according to the method of Fine, G. et al. (Fine, Morales, A. and Scerpella, J. R.: Arch. Path. 82: 4-8, 1966), by ligating the left anterior descending coronary artery (LAD). Six hours after the ligation, the rats were sacrificed, and the heart was immediately excised for analysis. In order to confirm the viability of myocardial cells (Fishbein, M. C. et al.: Am. Heart J. 101: 593-600, 1981), the inventors measured the area and size of myocardial infarction by staining with triphenyl tetrazolium chloride (TTC).
4.2 MK, anti-MK antibody, and anti.bFGF antibody MK and an affinity-purified rabbit anti-mouse MK antibody were prepared according to the method of Take, M. et al. (Take, M. et J. Biochem. 116: 1063-1068, 1994). The specificity of the affinity-purified anti-MK antibody was almost the same as that of the antibody described in Muramatsu et al. (Muramatsu, H. et al.: Dev. Biol. 159: 392-402, 1993). This antibody reacted with MK but not with PTN in the Western blot analysis. MAb52 (Wako Pure Chemicals) was used as the mouse antihuman bFGF monoclonal antibody. This antibody recognises the rat bFGF (Takami, K. et al: Exp.
Brain Res. 90: 1-10,1992).
4.3 Immunohistochemical analysis A horizontal cross section of the ventricular region of rat heart was taken out, fixed in a neutral buffer-formalin fixative at room temperature, embedded in paraffin, and cut into 5pm-thick sections.
After being deparaffinised, the sections were incubated in a 100% methanol containing 0.3% hydrogen peroxide solution for 30 min to block endogenous peroxidase. Bovine serum albumin was added to the sections, and the reaction was allowed to proceed for 30 min. In order to detect MK, [R:\LIBVVJ03001.doc:GDR ,r 14 these sections were incubated with the affinity-purified rabbit anti-MK polyclonal antibody (8pg/mL) at 4°C overnight. The sections were incubated with a biotinised goat anti-rabbit IgG antibody (Vector Laboratories Corp., California) for 30 min, and then with a biotinised alkaline phosphatase-streptavidin complex (Dako, Giostrup, Denmark) for 30 min. To detect bFGF, the sections were incubated with the mouse anti-bFGF monoclonal antibody (5pg/mL) at 4"C overnight, then with a biotinised rabbit antimouse antibody (Vector Laboratories Corp., California) for 30 min, and further with a biotinised alkaline phosphatase-streptavidin complex (Dako, Giostrup, Denmark) for 30 min. The immunoreaction was visualised with a Fast Red TR/Naphthol (Sigma, St. Louis, MO). Counterstaining was performed with haematoxylin. The specificity of MK immunostaining was determined by allowing recombinant MK to absorb the anti-MK antibody and subjecting the resulting complex to heparin- Sepharose affinity chromatography (Yasuhara, O. et Biochem. Biophys. Res. Commun,, 192: 246- 251, 1993).
The results are shown in Figs. 4 to 13.
Figures 4 to 7 are photomicrographs showing enhanced stainability of MK in rat heart after the is occlusion of the left anterior descending coronary artery. Figures 4 and 5 represent a normal, immunohistochemically stained rat heart, in which MK is expressed in some myocardial cells facing the ventricle. A weak immunoreaction is detected in other myocardial cells of the septum. However, most of myocardial cells express almost no MK. Figure 6 is a photomicrograph showing a rat heart six hours after the formation of myocardial infarction. Strong MK staining is detected in the septum the right ventricular wall and the endocardium (area indicated by an arrow) of the left ventricular wall The difference in the immunostaining between the left ventricular wall and the septum is very obvious. Stained and non-stained regions are divided by a single distinct border corresponding to the bordering region of each coronary artery that supplies nutrients to these regions.
Myocardial cells in the cell death region of LV are not stained. The MK expression pattern observed in the heart having a infarcted site was different from that of bFGF in the same heart. Figure 7 is a photomicrograph showing a control staining with a neutralising anti-MK antibody. Since cells were not stained after treatment with the neutralising anti-MK antibody, MK was confirmed to be stained specifically by this method. Bars shown in figures represent 1500 Dm in Figs. 4, 6 and 7, and 150 Om in Fig. Figures 8 to 13 are photomicrographs showing the detailed MK expression in a rat heart six hours after the formation of myocardial infarction. Immunohistochemical staining of MK was detected in the right ventricular wall (Fig. the septum (Figs. 9 and 11), the border region between the septum, the ventricular wall having infarcted areas, and the left ventricular wall (Fig. 10), the left ventricular wall (Fig. 12), and the endocardium within the left ventricle (Fig. 13). Immunoreaction of MK was observed in myocardial cells (portions indicated with asterisks in Figs. 11 and 13) and the penumbra of myocardial cells facing endothelial cells or endothelial cells themselves (portions indicated with an arrow and an arrowhead). In a high-magnification photomicrograph of the septum (Fig. 11), MK was intensely stained in the penumbra of myocardial cells facing the blood vessels or vascular endothelial cells. The inside of myocardial cells (Fig. 13) is also stained intensely or moderately (portions indicated with asterisks). The border between the septum and LV clearly [R:\LIBVV]03001 .doc:GDR S4 separates non-stained and stained regions (Fig. 10). Bars shown in figures represent 200pm in Figs.
8, 9 and 10, and 50 gm in Figs. 11, 12 and 13.
Example Measurement of MK in serum from infarction patient Using an EIA system described in JP-A Hei 10-160735, the inventors determined the MK concentration in sera from patients with myocardial infarction and cerebral infarction. Each serum sample collected from patients was centrifuged at 3000rpm for 15 min (at room temperature). These sera were stored at -80°C. Figure 14 shows an example of the periodically -determined MK concentration in serum from a patient with myocardial infarction. MK was expressed in the relatively early stage after development of myocardial infarction. Its concentration in blood increased and reached a peak 12 hours after the development. After 24 hours, it decreased to the same level as six hours after the development, and, after 31 hours, to about 0.16ng/mL, which is the average level of normal subjects. This change in the MK concentration in blood after the development of myocardial infarction is probably unique to MK. Such a correlation of myocardial infarction with MK, including the MK expression in the infarctic penumbra at the early stage, indicates the involvement of MK in the repair mechanism of cardiac muscle. Figure 15 shows the MK concentration in sera from cerebral infarction patients. In cerebral infarction cases also, MK was found in a very high concentration in blood from patients whose blood samples were thought to be collected at the early stage after the development of cerebral infarction such as in Figs. 15 A, D, E and F. These data are considered interesting in studying, at the individual level, the fact that a large amount of MK is detected near the area with cerebral infarction in an early stage after the development.
Industrial Applicability The midkine family proteins or partial peptides thereof according to this invention are efficacious in treating or preventing cytopathy caused by ischaemia, or ischaemic diseases due to said cytopathy. For example, these proteins are effective as medicaments for treating or preventing cerebrovascular disorders such as cerebrovascular spasm following subarachnoid haemorrhage, Alzheimer's disease, senile dementia of Alzheimer's type, cerebrovascular senile dementia, etc. as well as cerebral infarction, transient ischaemic diseases, and head trauma, and other cerebrovascular diseases such as Parkinson's disease, Huntington's chorea, amyotrophic regressive disorders, etc.
Furthermore, these proteins are expected to be used as medicaments for treating or preventing ischaemic diseases such as myocardial infarction or angina of effort; ischaemic colitis; superior mesenteric artery obstruction, etc.
In addition, these proteins can be expected to be used in gene therapy by activating promoters for genes of MK and PTN to express MK and PTN proteins in ischaemic sites.
[R:'LIBVV]03001 ,doc:GDR
Claims (15)
- 2. The method of claim 1, wherein said cytopathy caused by ischaemia or stress 0occurs in brain parenchyma. C 3. The method of claim 2, wherein said brain parenchyma is pyramidal cells in O the hippocampal CA1 area.
- 4. A method for treating or preventing cytopathy caused by ischaemia or stress in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition which is substantially as hereinbefore described with reference to any one of the Examples. A method for treating or preventing diseases caused by cytopathy due to ischaemia in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition comprising a midkine (MK) family protein as an active ingredient.
- 6. The method of claim 5, wherein said disease due to ischaemia is cerebral infarction.
- 7. The method of claim 5, wherein said disease due to ischaemia is myocardial infarction.
- 8. A method for treating or preventing cerebral infarction caused by cytopathy due to stress in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition comprising a midkine (MK) family protein as an active ingredient.
- 9. A method for treating or preventing diseases caused by cytopathy due to ischaemia or stress in a mammal in need of such treatment or prevention, the method comprising administering to said mammal a pharmaceutical composition which is substantially as hereinbefore described with reference to any one of the Examples.
- 10. Use of a midkine (MK) family protein for the manufacture of a medicament for treating or preventing cytopathy caused by ischaemia or stress. S11. The use according to claim 10, wherein said cytopathy caused by ischaemia or stress occurs in brain parenchyma. \D 12. The use according to claim 11, wherein said brain parenchyma is pyramidal cells in the hippocampal CA1 area.
- 13. Use of a midkine (MK) family protein in the manufacture of a medicament for c treating or preventing diseases caused by cytopathy due to ischaemia.
- 014. The use according to claim 13, wherein said disease due to ischaemia is aC cerebral infarction. The use according to claim 13, wherein said disease due to ischaemia is myocardial infarction.
- 16. Use of a midkine (MK) family protein in the manufacture of a medicament for treating or preventing cerebral infarction caused by cytopathy due to stress.
- 17. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing cytopathy caused by ischaemia or stress in a mammal.
- 18. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing cytopathy caused by ischaemia or stress in a mammal, wherein said cytopathy occurs in brain parenchyma.
- 19. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing cytopathy caused by ischaemia or stress in a mammal, wherein said cytopathy occurs in brain parenchyma which is pyramidal cells in the hippocampal CA1 area. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases caused by cytopathy due to ischaemia in a mammal.
- 21. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases caused by cytopathy due to ischaemia or stress in a mammal, wherein said disease is cerebral infarction.
- 22. A midkine (MK) family protein or a pharmaceutical composition comprising an MK protein as an active ingredient when used for treating or preventing diseases T 1 r1 1 1 71-11-I 1 T- caused by cytopathy due to ischaemia in a mammal, wherein said disease is myocardial infarction. Dated 25 July, 2005 Yoshihiro Yoshida Takashi Muramatsu CN Patent Attorneys for the Applicants/Nominated Persons SPRUSON FERGUSON (N r- rn l n 4nF T i-^.'TTDrt
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003200309A AU2003200309B2 (en) | 1997-09-26 | 2003-01-31 | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9-279435 | 1997-09-26 | ||
AU91851/98A AU9185198A (en) | 1997-09-26 | 1998-09-25 | Preventives or remedies for ischemic diseases |
AU2003200309A AU2003200309B2 (en) | 1997-09-26 | 2003-01-31 | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU91851/98A Division AU9185198A (en) | 1997-09-26 | 1998-09-25 | Preventives or remedies for ischemic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003200309A1 AU2003200309A1 (en) | 2003-04-17 |
AU2003200309B2 true AU2003200309B2 (en) | 2005-08-18 |
Family
ID=39277070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003200309A Ceased AU2003200309B2 (en) | 1997-09-26 | 2003-01-31 | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2003200309B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017081224A1 (en) * | 2015-11-12 | 2017-05-18 | Celltrend Gmbh | Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827021A (en) * | 1994-07-22 | 1996-01-30 | Mitsui Toatsu Chem Inc | Medicinal composition |
-
2003
- 2003-01-31 AU AU2003200309A patent/AU2003200309B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827021A (en) * | 1994-07-22 | 1996-01-30 | Mitsui Toatsu Chem Inc | Medicinal composition |
Non-Patent Citations (2)
Title |
---|
Nobuhiko Iwashita et al., The Journal of Japanese Biochemical Industry (Seikagaku), 68 (7), 1996, p 846 * |
Takashi Muramatsu, The Journal of Japanese Biochemical Industry (Seikagaku), 66 (7), 1994, p 611 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017081224A1 (en) * | 2015-11-12 | 2017-05-18 | Celltrend Gmbh | Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kretz et al. | Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation | |
JP5400006B2 (en) | Preventive or therapeutic agent for ischemic disease | |
EA013966B1 (en) | Use of erythropoietin for treatment of diabetes melitus | |
KR101757523B1 (en) | Antisecretory protein for use in the treatment of compartment syndrome | |
JP2008530003A (en) | Use of a myostatin (GDF-8) antagonist for improving wound healing and for preventing fibrosis | |
HU206988B (en) | Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient | |
KR20020035855A (en) | Brain cell or nerve cell protecting agents comprising ginseng | |
US20040209812A1 (en) | Use of erythropoietin in stroke recovery | |
HU229628B1 (en) | Angiogenesis and vascular permeability modulators and inhibitors | |
EP2200630A1 (en) | Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 | |
WO1997035609A1 (en) | Neovascularization inhibitor containing tissue factor pathway inhibitor | |
US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
JPH09502451A (en) | Compositions and methods for stimulating platelet production using unbound MPL receptors | |
US6468960B1 (en) | Therapeutic compositions and methods for enhancing angiogenesis | |
AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
JP7002788B2 (en) | Pharmaceutically acceptable salts of polypeptides and their use | |
JP2020536065A (en) | Therapeutic peptide composition for injuries associated with excitatory neurotoxicity | |
DE60110247T2 (en) | Angiogenic tri- or tetrapeptides derived from AcSDKP | |
WO2023222051A1 (en) | Use of mif and ripk1 in perioperative ischemic brain injuries | |
US20060275303A1 (en) | Modulating angiogenesis using LL-37/HCAP-18 | |
US20050079151A1 (en) | Therapeutic agents for apoptosis-related diseases | |
JP2001010972A (en) | Cytoprotective agent comprising peptide relating to prosaposin | |
WO2024005133A1 (en) | Therapeutic agent for meniscus | |
EP1097717A1 (en) | Remedies for apoptosis-associated diseases | |
ZA200508695B (en) | Use of erythropoietin in stroke recovery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: YOSHIDA, YOSHIHIRO; MURAMATSU, TAKASHI Free format text: FORMER APPLICANT(S): MEIJI MILK PRODUCTS CO., LTD. |
|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: MEDICAL THERAPIES LIMITED Free format text: FORMER OWNER WAS: MURAMATSU, TAKASHI; YOSHIDA, YOSHIHIRO |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |